Ionis Pharmaceuticals (IONS)

$70.86 -0.64 (-0.90%)
Market Cap 11.40B
Revenue (ttm) 705.14M
Net Income (ttm) -453.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -64.37%
Debt to Equity Ratio 0.09
Volume 1,990,300
Avg Vol 2,556,316
Day's Range N/A - N/A
Shares Out 159.39M
Stochastic %K 18%
Beta 0.33
Analysts Strong Sell
Price Target $76.09

Company Profile

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 931 9200
Address:
2855 Gazelle Court, Carlsbad, United States
BioRich
BioRich Oct. 25 at 5:10 AM
$ALT Thanks to Mr. 32K Shares for trying to pump $SNY as hopeful suitor showing pity on the dying quail, ALT. It motivated to use this boards favorite tool (AI) and ask: "If Sanofi were to buy a MASH company, who would they buy?" Answer: 1) $MDGL 2) $IVA 3) $IONS My pick is $IVA. I think a deal is done and they are just waiting for the ink to dry. Sorry ALT Nation, no mention of $ALT. Not for buyout. Not for partnership. Not for licensing. ChatGPT didn't even acknowledge $ALT was a player when it listed off other potential candidates.
0 · Reply
Anastasia99
Anastasia99 Oct. 25 at 1:10 AM
$IONS
0 · Reply
JFDI
JFDI Oct. 24 at 8:14 PM
$IONS > $IONQ
0 · Reply
Gaox01
Gaox01 Oct. 24 at 11:45 AM
$IONS Ionis Ionis has been named #2 employer by Science magazine 2025. https://ir.ionis.com/news-releases/news-release-details/ionis-ranked-2-top-employer-science-magazine-recognizing#:~:text=Release%20Details-,Ionis%20ranked%20%232%20Top%20Employer%20by%20Science%20magazine%2C%20recognizing%20industry,scientific%20innovation%20and%20company%20culture
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 1:19 PM
Enter: $IONS NOV 21 2025 $72 CALLS Buy in Price: $4.40 - $6.20 Take Profit: $9.72 Stop Bleeding: $3.87 ROI Potential: 121% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 5:58 PM
Morgan Stanley has updated their rating for Ionis Pharmaceuticals ( $IONS ) to Overweight with a price target of 90.
0 · Reply
Thenextgme
Thenextgme Oct. 9 at 3:58 PM
$IONS posts like this tell me people lack experience. They will buy the stock at 20$ thinking there is still value. We will read about them in the newspaper, lost all their money committed suicide
1 · Reply
RoyalPurp
RoyalPurp Oct. 8 at 11:05 PM
$IONS She’s moving
0 · Reply
ZorTrades
ZorTrades Oct. 8 at 6:53 PM
Barron’s out cautious on $RGTI $QBTS $IONS $QUBT —- I wonder if the Eiffel tower pattern was part of their analysis.😭 ($IONZ, $QBTZ)
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 4:24 PM
Needham updates rating for Ionis Pharmaceuticals ( $IONS ) to Buy, target set at 70 → 78.
0 · Reply
Latest News on IONS
Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

Oct 23, 2025, 2:10 PM EDT - 2 days ago

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

Oct 21, 2025, 8:00 AM EDT - 4 days ago

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

Ionis to hold third quarter 2025 financial results webcast

Oct 16, 2025, 7:05 AM EDT - 9 days ago

Ionis to hold third quarter 2025 financial results webcast

Ionis Pharmaceuticals, Inc. (IONS) Shareholder/Analyst Call Transcript

Oct 7, 2025, 8:55 PM EDT - 17 days ago

Ionis Pharmaceuticals, Inc. (IONS) Shareholder/Analyst Call Transcript

Ionis Pharmaceuticals CEO Brett Monia on the drugs they are focused on

Oct 7, 2025, 8:33 AM EDT - 18 days ago

Ionis Pharmaceuticals CEO Brett Monia on the drugs they are focused on

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

Oct 7, 2025, 7:00 AM EDT - 18 days ago

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial

Sep 22, 2025, 9:06 AM EDT - 4 weeks ago

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial

Ionis' brain disorder drug shows promise in clinical trial

Sep 22, 2025, 7:10 AM EDT - 4 weeks ago

Ionis' brain disorder drug shows promise in clinical trial

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

Sep 22, 2025, 7:00 AM EDT - 4 weeks ago

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

Sep 19, 2025, 7:00 AM EDT - 5 weeks ago

TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

Sep 12, 2025, 7:00 AM EDT - 6 weeks ago

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

Ionis: Recent Approvals, Upcoming Catalysts To Spur Strong Upside (Rating Upgrade)

Sep 11, 2025, 2:14 AM EDT - 6 weeks ago

Ionis: Recent Approvals, Upcoming Catalysts To Spur Strong Upside (Rating Upgrade)

Ionis Pharmaceuticals, Inc. (IONS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 6:11 PM EDT - 6 weeks ago

Ionis Pharmaceuticals, Inc. (IONS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status

Sep 9, 2025, 1:51 PM EDT - 6 weeks ago

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

Sep 9, 2025, 7:00 AM EDT - 6 weeks ago

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

Ionis Pharmaceuticals, Inc. (IONS) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)

Sep 8, 2025, 5:33 PM EDT - 6 weeks ago

Ionis Pharmaceuticals, Inc. (IONS) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)

Ionis to host investors and analysts for Innovation Day 2025

Sep 8, 2025, 4:00 PM EDT - 6 weeks ago

Ionis to host investors and analysts for Innovation Day 2025

Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 4, 2025, 1:47 PM EDT - 7 weeks ago

Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Is The 35% Rally In IONS Stock Just The Beginning?

Sep 3, 2025, 10:41 AM EDT - 7 weeks ago

Is The 35% Rally In IONS Stock Just The Beginning?

Ionis to present at upcoming investor conferences

Sep 2, 2025, 4:00 PM EDT - 7 weeks ago

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (IONS) Positive CORE And CORE2 Topline Results (Transcript)

Sep 2, 2025, 12:26 PM EDT - 7 weeks ago

Ionis Pharmaceuticals, Inc. (IONS) Positive CORE And CORE2 Topline Results (Transcript)

Ionis Pharmaceuticals stock rockets 31% to new 52-week high on breakthrough news

Sep 2, 2025, 11:17 AM EDT - 7 weeks ago

Ionis Pharmaceuticals stock rockets 31% to new 52-week high on breakthrough news

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Sep 2, 2025, 10:38 AM EDT - 7 weeks ago

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Ionis shares jump after drug lowers blood fat levels in advanced trials

Sep 2, 2025, 9:25 AM EDT - 7 weeks ago

Ionis shares jump after drug lowers blood fat levels in advanced trials

Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)

Sep 2, 2025, 7:00 AM EDT - 7 weeks ago

Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 2 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN MRNA RGEN

Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma

Aug 26, 2025, 3:50 PM EDT - 2 months ago

Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma

US FDA approves Ionis' drug for rare genetic disorder

Aug 21, 2025, 11:58 AM EDT - 2 months ago

US FDA approves Ionis' drug for rare genetic disorder

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Aug 21, 2025, 11:45 AM EDT - 2 months ago

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:42 PM EDT - 3 months ago

Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

Jul 30, 2025, 2:34 PM EDT - 3 months ago

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

Ionis reports second quarter 2025 financial results and highlights progress on key programs

Jul 30, 2025, 7:00 AM EDT - 3 months ago

Ionis reports second quarter 2025 financial results and highlights progress on key programs

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

Jul 25, 2025, 7:15 AM EDT - 3 months ago

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases

Jul 23, 2025, 7:41 AM EDT - 3 months ago

Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

Jul 21, 2025, 7:00 AM EDT - 3 months ago

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

Ionis to hold second quarter 2025 financial results webcast

Jul 16, 2025, 7:05 AM EDT - 3 months ago

Ionis to hold second quarter 2025 financial results webcast

Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight

Jun 29, 2025, 1:04 PM EDT - 4 months ago

Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

Jun 25, 2025, 7:31 AM EDT - 4 months ago

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

Jun 12, 2025, 9:00 AM EDT - 4 months ago

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Jun 11, 2025, 7:00 AM EDT - 4 months ago

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

May 19, 2025, 7:00 AM EDT - 5 months ago

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

Ionis to host 2025 virtual Annual Meeting of Stockholders

May 6, 2025, 7:05 AM EDT - 6 months ago

Ionis to host 2025 virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 2:20 PM EDT - 6 months ago

Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Apr 30, 2025, 2:05 PM EDT - 6 months ago

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Ionis reports first quarter 2025 financial results

Apr 30, 2025, 7:00 AM EDT - 6 months ago

Ionis reports first quarter 2025 financial results

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

Apr 29, 2025, 7:00 AM EDT - 6 months ago

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)

Apr 22, 2025, 2:12 PM EDT - 6 months ago

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)

Ionis to host expert panel discussion on sHTG

Apr 3, 2025, 7:05 AM EDT - 7 months ago

Ionis to host expert panel discussion on sHTG

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

Mar 26, 2025, 7:00 AM EDT - 7 months ago

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera

Mar 11, 2025, 6:00 PM EDT - 8 months ago

Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera

BioRich
BioRich Oct. 25 at 5:10 AM
$ALT Thanks to Mr. 32K Shares for trying to pump $SNY as hopeful suitor showing pity on the dying quail, ALT. It motivated to use this boards favorite tool (AI) and ask: "If Sanofi were to buy a MASH company, who would they buy?" Answer: 1) $MDGL 2) $IVA 3) $IONS My pick is $IVA. I think a deal is done and they are just waiting for the ink to dry. Sorry ALT Nation, no mention of $ALT. Not for buyout. Not for partnership. Not for licensing. ChatGPT didn't even acknowledge $ALT was a player when it listed off other potential candidates.
0 · Reply
Anastasia99
Anastasia99 Oct. 25 at 1:10 AM
$IONS
0 · Reply
JFDI
JFDI Oct. 24 at 8:14 PM
$IONS > $IONQ
0 · Reply
Gaox01
Gaox01 Oct. 24 at 11:45 AM
$IONS Ionis Ionis has been named #2 employer by Science magazine 2025. https://ir.ionis.com/news-releases/news-release-details/ionis-ranked-2-top-employer-science-magazine-recognizing#:~:text=Release%20Details-,Ionis%20ranked%20%232%20Top%20Employer%20by%20Science%20magazine%2C%20recognizing%20industry,scientific%20innovation%20and%20company%20culture
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 1:19 PM
Enter: $IONS NOV 21 2025 $72 CALLS Buy in Price: $4.40 - $6.20 Take Profit: $9.72 Stop Bleeding: $3.87 ROI Potential: 121% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 5:58 PM
Morgan Stanley has updated their rating for Ionis Pharmaceuticals ( $IONS ) to Overweight with a price target of 90.
0 · Reply
Thenextgme
Thenextgme Oct. 9 at 3:58 PM
$IONS posts like this tell me people lack experience. They will buy the stock at 20$ thinking there is still value. We will read about them in the newspaper, lost all their money committed suicide
1 · Reply
RoyalPurp
RoyalPurp Oct. 8 at 11:05 PM
$IONS She’s moving
0 · Reply
ZorTrades
ZorTrades Oct. 8 at 6:53 PM
Barron’s out cautious on $RGTI $QBTS $IONS $QUBT —- I wonder if the Eiffel tower pattern was part of their analysis.😭 ($IONZ, $QBTZ)
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 4:24 PM
Needham updates rating for Ionis Pharmaceuticals ( $IONS ) to Buy, target set at 70 → 78.
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 3:51 PM
Oppenheimer has updated their rating for Ionis Pharmaceuticals ( $IONS ) to Outperform with a price target of 90.
0 · Reply
briefingcom
briefingcom Oct. 8 at 12:47 PM
$IONS: Ionis Pharma upgraded to Overweight from Neutral at JP Morgan, tgt $80 View More Stock Upgrades: https://www.briefing.com/calendars/updown?Filter=upgrades&utm_campaign=updown&utm_medium=social&utm_source=st&utm_content=link
0 · Reply
notreload_ai
notreload_ai Oct. 8 at 12:20 PM
JPMorgan analyst upgrades $IONS to Overweight, raising price target to $80 from $49, citing strong drug launches and path to profitability. https://notreload.xyz/jpmorgan-boosts-ionis-stock-rating-strong-drug-pipeline/
0 · Reply
ChessGM
ChessGM Oct. 8 at 12:10 PM
$IONS JP Morgan Upgrades Ionis Pharmaceuticals to Overweight, Raises Price Target to $80
0 · Reply
Quantumup
Quantumup Oct. 8 at 11:48 AM
H.C. Wainwright reiterated $ARWR Buy-$80/said, With the November 18 PDUFA action date for plozasiran in familial chylomicronemia syndrome (FCS) approaching, we conducted several calls with Arrowhead management and key opinion leaders (KOLs) in the space. $IONS H.C. Wainwright added:
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 10:18 AM
HC Wainwright & Co. updates rating for Ionis Pharmaceuticals ( $IONS ) to Buy, target set at 95.
0 · Reply
johnnygogogo
johnnygogogo Oct. 7 at 5:59 PM
$IONS wonder which bank got the CEO booked on CNBC / Squawk Box (it wasn’t their own PR department, I’ll tell you that much). Best guess is Goldman or Morgan Scamley and it has to do with pumping the convertible debt. (“For its June 2023 convertible senior notes offering, Ionis Pharmaceuticals worked with multiple "initial purchasers," including affiliates of Morgan Stanley and Goldman Sachs. The law firm Cooley LLP advised Ionis on the offering. “) cc @skeezbag
1 · Reply
itsmetradingstocks
itsmetradingstocks Oct. 7 at 3:57 PM
$IONS 2028 CF positive
1 · Reply
Im_a_realist
Im_a_realist Oct. 7 at 11:34 AM
$IONS CEO says "we'll make money or we won't make money" when asked if he has concerns about going after rare diseases. WTF kinda answer is that? So much for share holders long term.
1 · Reply
JarvisFlow
JarvisFlow Oct. 6 at 12:24 PM
Stifel updates rating for Ionis Pharmaceuticals ( $IONS ) to Hold, target set at 43 → 67.
0 · Reply
FloatFrenzy
FloatFrenzy Oct. 5 at 8:01 AM
$IONS Biopharmaceutical focus. Trading near cash value. High short interest. Binary event risk on data.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 4 at 1:10 AM
Enter: $IONS NOV 21 2025 $68 CALLS Buy in Price: $3.95 - $5.60 Take Profit: $7.43 Stop Bleeding: $3.48 ROI Potential: 88% Exit Within: 174 Minutes https://moneygroup.us/alerts
0 · Reply